Biogen (BIIB) FY2025 10-K Risk Factors: 6 New, 5 Dropped

What the changes say

Biogen highlights risks from healthcare reform laws like PPACA, IRA, and OBBBA impacting drug reimbursement.

What changed since the prior 10-K

New

NewRisks Related to Our Business
We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations
We invest heavily in unapproved products and struggle to find viable external acquisition or in-licensing candidates.
NewRisks Related to Our Business
Our results of operations may be adversely affected by current and potential future healthcare reforms including those contained in the PPACA, IRA, OBBBA, MFN and executive orders
Healthcare reforms like PPACA, IRA, and OBBBA increase Medicaid rebates and pricing pressures on our prescription drugs.
NewRisks Related to Our Business
pharmaceuticals, limit our ability to launch products in certain markets and impact healthcare systems and drug markets in the U.S. and abroad, thereby negatively affecting our revenue and adversely impacting our business
State-level budget constraints, price controls, and drug importation laws threaten our product revenues.
NewRisks Related to Our Operations
technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information
Cybersecurity threats and evolving data privacy regulations expose us to operational disruption and monetary fines.
NewRisks Related to Our Operations
We built a large-scale biologics manufacturing facility and are building a clinical packaging and other manufacturing facility, which represent a significant investment with no assurance that such investment will be recouped
Our large-scale biologics manufacturing facility in Solothurn, Switzerland carries excess capacity risk if regulatory approvals or demand fall short.
NewRisks Related to Our Operations
Additionally, we are building a new clinical packaging and other manufacturing facility as well as modernizing and automating our existing manufacturing facilities in RTP with no assurance that these investments will be fully utilized
We face financial risks if our new clinical packaging and modernized facilities in RTP are not fully utilized.

Dropped

DroppedRisks Related to Our Business
While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth
DroppedRisks Related to Our Business
Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations
DroppedRisks Related to Our Business
Our results of operations may be adversely affected by current and potential future healthcare reforms
DroppedRisks Related to Our Operations
may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support
DroppedRisks Related to Our Operations
Although the Solothurn facility was approved by the FDA for LEQEMBI, there can be no assurance that the regulatory authorities will approve the Solothurn facility for the manufacturing of other products
Internal pipeline delays increase reliance on external development.

Reworded

71% rewrittenRisks Related to Our Business
Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives
Added specific mention of risks from pipeline delays and commercial execution issues impacting growth.
56% rewrittenRisks Related to Our Operations
If we fail to comply with the extensive legal and regulatory requirements affecting the healthcare industry, we could face increased costs, penalties and a loss of business
Maintained broad regulatory compliance scope with negligible wording adjustments.
Was: If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business
46% rewrittenRisks Related to Holding Our Common Stock
Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements
Updated OECD Pillar Two minimum global tax references, including the January 2026 OECD package.
44% rewrittenRisks Related to Our Operations
A breakdown or breach of our information systems could subject us to liability or interrupt our business operations
Retained remote work and cloud technology risk language with minor stylistic tweaks.
Was: A breakdown or breach of our information systems could subject us to liability or interrupt the operation of our business
34% rewrittenRisks Related to Holding Our Common Stock
Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts in our financial statements
Changed global biopharmaceutical company reference to global company for tax purposes.
34% rewrittenRisks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates
Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price
Clarified that adverse safety issues have caused and may cause regulatory scrutiny and labeling changes.
32% rewrittenRisks Related to Our Business
Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful, our business may be adversely affected
Added specific examples of contract manufacturers for IMRALDI and BENEPALI acquired by third parties in 2024.
Was: Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected
30% rewrittenRisks Related to Our Business
Our long-term success depends upon the successful development of new products and additional indications for our existing products
Minor phrasing updates regarding product development uncertainty and new indication research.
30% rewrittenRisks Related to Our Operations
Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products
27% rewrittenRisks Related to Our Operations
The increasing use of AI-based software presents new risks and challenges and could adversely affect our business and reputation
23% rewrittenRisks Related to Our Operations
Our sales and operations are subject to the risks of doing business internationally
22% rewrittenRisks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates
Successful preclinical work or early/late stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product
Was: Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product

All 35 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Business

01We are substantially dependent on revenue from our products
02Our long-term success depends upon the successful development of new products and additional indications for our existing products30% rewritten
03If we fail to compete effectively, our business and market position would suffer
04Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives71% rewritten
05We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operationsNew
06Our results of operations may be adversely affected by current and potential future healthcare reforms including those contained in the PPACA, IRA, OBBBA, MFN and executive ordersNew
07pharmaceuticals, limit our ability to launch products in certain markets and impact healthcare systems and drug markets in the U.S. and abroad, thereby negatively affecting our revenue and adversely impacting our businessNew
08Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful, our business may be adversely affected32% rewritten

Risks Related to Intellectual Property

09If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed

Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates

10Successful preclinical work or early/late stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product22% rewritten
11Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied
12Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price34% rewritten

Risks Related to Our Operations

13A breakdown or breach of our information systems could subject us to liability or interrupt our business operations44% rewritten
14technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety informationNew
15The increasing use of AI-based software presents new risks and challenges and could adversely affect our business and reputation27% rewritten
16Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue
17Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products30% rewritten
18In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations
19If we fail to comply with the extensive legal and regulatory requirements affecting the healthcare industry, we could face increased costs, penalties and a loss of business56% rewritten
20Additionally, conditions and regulations governing the healthcare industry in the U.S. are subject to greater risk of change and uncertainty as a result of changes in legislative and regulatory priorities and personnel
21Our sales and operations are subject to the risks of doing business internationally23% rewritten
22We built a large-scale biologics manufacturing facility and are building a clinical packaging and other manufacturing facility, which represent a significant investment with no assurance that such investment will be recoupedNew
23Additionally, we are building a new clinical packaging and other manufacturing facility as well as modernizing and automating our existing manufacturing facilities in RTP with no assurance that these investments will be fully utilizedNew
24The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business
25The increasing use of social media platforms presents new risks and challenges

Risks Related to Holding Our Common Stock

26Our operating results are subject to significant fluctuations
27Our investments in properties may not be fully realized
28We may not be able to access the capital and credit markets on favorable terms, which could increase financing costs
29Our indebtedness could adversely affect us and limit our ability to plan for or respond to changes in our business
30Our investment portfolio is subject to market, interest and credit risk that may reduce its value
31There can be no assurance that we will repurchase shares or that we will repurchase shares at favorable prices, which may negatively affect our stock price
32Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us
33Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts in our financial statements34% rewritten
34Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements46% rewritten
35Our business involves environmental and operational risks, which include the cost of compliance and the risk of contamination or injury

Other Biogen 10-Ks

FY2024 10-K risk factors
34 risks
Heavy reliance on key product revenues and anti-CD20 therapeutic programs in competitive markets.
Filed Feb 12, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.